subspecialists may favor a different management strategy. We encourage rheumatologists to discuss treatment plans and coordinate care with other subspecialists as needed. Recently, a clinical trial of avacopan in patients with GPA and MPA was published This guideline highlights gaps in our knowledge for the treatment of AAV. Most glaring is the lack of biomarker assessments or other noninvasive diagnostic testing with minimal toxicity that can accurately assess disease activity and predict